General Motors Co. (GM) is rising 4 percent to $31.40. The company's first quarter earnings declined from the previous year period. Net revenue fell from the year-ago quarter, but managed to come above the consensus estimate.
Ford Motor Co. (F) is up over 1 percent to $13.57. The company announced that its Kansas City Assembly Plant would add more than 2,000 jobs to meet surging demand for the Ford F-150 and planned production of the all-new Ford Transit.
Facebook, Inc. (FB) is rising more than 1 percent to $27.91. The company's first quarter profit improved from the prior year period, but was below Wall Street view. Revenue for the quarter rose 38 percent and managed to come above the consensus estimate.
Beazer Homes USA Inc. (BZH) is gaining 6 percent to $17.80. The company's second quarter net loss narrowed from the prior year period. Revenue for the quarter surged and topped the consensus estimate. The company also expects to report positive net income for its fiscal fourth quarter, which should allow it to be profitable for the second half of fiscal 2013.
NII Holdings Inc. (NIHD) is rising 9 percent to $9.10. The company slipped to a loss in its first quarter. Operating revenue declined and missed the consensus estimate. The company also announced the appointment of Steven Shindler to the permanent position of chief executive officer. Shindler had been holding the dual role of chairman and interim chief executive role. The company also plans to separate the positions of chairman and chief executive and to appoint a non-executive chairman in the near future.
Catamaran Corp. (CTRX) is falling 5 percent to $54.20. The company's first quarter profit surged from the year-ago quarter and its adjusted earnings per share topped Wall Street view. Revenue surged 88 percent, but missed the consensus estimate. The company affirmed its full year 2013 guidance.
Trading in shares of AVEO Pharmaceuticals, Inc. (AVEO) was halted. The FDA's Oncologic Drugs Advisory Committee meets today to discuss the new drug application for tivozanib for the treatment of patients with advanced renal cell carcinoma.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org